Mexico Cardiovascular Drugs Market Analysis Report 2022 to 2030

Mexico Cardiovascular Drugs Market Analysis

$ 3999

Mexico Cardiovascular Drug Market is at around $2.1 Bn in 2022 and is projected to reach $2.9 Bn in 2030, exhibiting a CAGR of 4.05% during the forecast period. Increased prevalence of disease, greater awareness, and strategic partnerships between pharmaceutical companies and healthcare providers are driving the market. The market is dominated by key players like Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., and F. Hoffman-La Roche Ltd.

ID: IN10MXPH007 CATEGORY: Pharmaceuticals GEOGRAPHY: Mexico AUTHOR: Aneri Parekh

Buy Now

Mexico Cardiovascular Drug Market Executive Summary

Mexico Cardiovascular Drug Market is at around $2.1 Bn in 2022 and is projected to reach $2.9 Bn in 2030, exhibiting a CAGR of 4.05% during the forecast period.

Cardiovascular diseases are disorders of the heart and blood vessels as a whole. These include coronary heart disease, rheumatic heart disease, peripheral artery disease, congenital heart disease, pulmonary embolism, and deep vein thrombosis. Angiotensin-II antagonists (like losartan), antiarrhythmics (like amiodarone), and ACE inhibitors (like ramipril) are the three main classes of medications used to treat heart-related issues.

More than 60% of CVD deaths in Mexico are attributable to ischemic heart disease. The aging population, changing lifestyles, and growing knowledge of cardiovascular health have all had an impact on the Mexican cardiovascular industry. Mexico is seeing an increase in the prevalence of cardiovascular illnesses, such as hypertension and coronary artery disease, which is fueling the market for cardiovascular medications. Mexican pharmaceutical companies have concentrated on creating and selling antiplatelet agents, antihypertensive medicines, and statins to treat common cardiovascular disorders.

Global revenue for the pharmaceutical sector reached $138.33 Bn in 2022, a significant increase over the preceding 20 years. The aging population and growing prevalence of cardiovascular disorders are driving the market for cardiovascular medications. More awareness and improved diagnostics, enabling earlier detection and treatment, will also drive the demand.

Pfizer's market share in Mexico for cardiovascular drugs is approximately 15%. Their anticoagulant leader, Eliquis (apixaban), is well-known, and Lipitor (atorvastatin), which lowers cholesterol, is a household brand. Pfizer's position as a true cardiac powerhouse in Mexico is cemented by its vast reach and tailored products for hypertension.

Mexico cardiovascular drug market

Market Dynamics

Market Growth Drivers:

Rising Prevalence of Cardiovascular Diseases: Growth of the market is driven by variables such as aging populations, sedentary lifestyles, and dietary patterns leading to increased prevalence of the disease.

Increased Awareness & Improved Facility: Heart health awareness and improvements in medical facilities enable early diagnosis and treatment, which promotes market expansion.

Partnership & Collaborations: The market is growing as a result of partnerships between pharmaceutical companies and healthcare providers as well as legislative measures that support cardiovascular health are aiding the growth.

Market Restraints:

Regulatory Obstacles: Complicated licensing procedures and strict regulatory frameworks for novel cardiovascular drugs can be barriers that impede innovation and market access.

Cultural and Factors: Behavioural factors can pose significant difficulties to the efficiency of cardiovascular therapy and market dynamics. These include patient adherence to prescribed treatments and cultural attitudes.

Healthcare Policies and Regulatory Landscape

Mexican Secretariat of Health, or Secretaría de Salud, is the organization in charge of overseeing pharmaceutical and medical device regulations as well as other facets of health services, including national health policy. The Sanitary Authorization Commission (CAS), which has jurisdiction over the sanitary registration of pharmaceuticals in Mexico, works with the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) to oversee the procedure. Requests and technical meetings for the New Molecule Committee of COFEPRIS are handled by the Center for Integrated Services (Centro Integral de Servicios, CIS). The Mexican government places a high priority on accessible healthcare and strictly regulates medicine prices. This can be a significant barrier for novel, expensive drugs, making it difficult for businesses to recover their initial expenditures.

Competitive Landscape

Key Players:

Bristol-Myers Squibb Company
Pfizer Inc.
Bayer AG
Janssen Pharmaceuticals, Inc.
AstraZeneca
Sanofi
Novartis AG
Merck & Co., Inc.
Gilead Sciences, Inc.
F. Hoffmann-La Roche Ltd

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Mexico Cardiovascular Drug Market Segmentation

By Drug Type

Cephalosporins
Antihypertensive
Antihyperlipidemic
Anticoagulants
Antiplatelet Drug
Others

By Disease Indication

Hypertension
Hyperlipidemia
Coronary Artery Disease
Arrhythmia
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.